38211979|t|Amyloid Modifier SERF1a Accelerates Alzheimer's Amyloid-beta Fibrillization and Exacerbates the Cytotoxicity.
38211979|a|Alzheimer's disease (AD) is a devastating, progressive neurodegenerative disease affecting the elderly in the world. The pathological hallmark senile plaques are mainly composed of amyloid-beta (Abeta), in which the main isoforms are Abeta40 and Abeta42. Abeta is prone to aggregate and ultimately forms amyloid fibrils in the brains of AD patients. Factors that alter the Abeta aggregation process have been considered to be potential targets for treatments of AD. Modifier of aggregation 4 (MOAG-4)/small EDRK-rich factor (SERF) was previously selected from a chemical mutagenesis screen and identified as an amyloid modifier that promotes amyloid aggregation for alpha-synuclein, huntingtin, and Abeta40. The interaction and effect of yeast ScSERF on Abeta40 were previously described. Here, we examined the human SERF1a effect on Abeta40 and Abeta42 fibrillization by the Thioflavin T assay and found that SERF1a accelerated Abeta fibrillization in a dose-dependent manner without changing the fibril amount and without incorporation. By Fourier transform infrared spectroscopy (FTIR) and transmission electron microscopy (TEM), we found that SERF1a altered the secondary structures and the morphology of Abeta fibrils. The electrospray ionization mass spectrometry (ESI-MS) and analytical ultracentrifugation (AUC) results showed that SERF1a binds to Abeta in a 1:1 stoichiometry. Moreover, the NMR study showed that SERF1a interacts with Abeta via its N-terminal region. Cytotoxicity assay demonstrated that SERF1a enhanced toxicity of Abeta intermediates, and the effect can be rescued by SERF1a antibody. Overall, our study provides the underlying molecular mechanism for the SERF1a effect on Abeta fibrillization and facilitates the therapeutic development of AD.
38211979	0	7	Amyloid	Disease	MESH:C000718787
38211979	17	23	SERF1a	Gene	8293
38211979	36	47	Alzheimer's	Disease	MESH:D000544
38211979	48	60	Amyloid-beta	Gene	351
38211979	96	108	Cytotoxicity	Disease	MESH:D064420
38211979	110	129	Alzheimer's disease	Disease	MESH:D000544
38211979	131	133	AD	Disease	MESH:D000544
38211979	165	190	neurodegenerative disease	Disease	MESH:D019636
38211979	253	267	senile plaques	Disease	MESH:D058225
38211979	291	303	amyloid-beta	Gene	351
38211979	305	310	Abeta	Gene	351
38211979	356	363	Abeta42	Gene	351
38211979	365	370	Abeta	Gene	351
38211979	414	421	amyloid	Disease	MESH:C000718787
38211979	447	449	AD	Disease	MESH:D000544
38211979	450	458	patients	Species	9606
38211979	483	488	Abeta	Gene	351
38211979	572	574	AD	Disease	MESH:D000544
38211979	721	728	amyloid	Disease	MESH:C000718787
38211979	752	771	amyloid aggregation	Disease	MESH:C000718787
38211979	776	791	alpha-synuclein	Gene	6622
38211979	793	803	huntingtin	Gene	3064
38211979	848	853	yeast	Species	4932
38211979	921	926	human	Species	9606
38211979	927	933	SERF1a	Gene	8293
38211979	956	963	Abeta42	Gene	351
38211979	986	998	Thioflavin T	Chemical	MESH:C009462
38211979	1020	1026	SERF1a	Gene	8293
38211979	1039	1044	Abeta	Gene	351
38211979	1257	1263	SERF1a	Gene	8293
38211979	1319	1324	Abeta	Gene	351
38211979	1450	1456	SERF1a	Gene	8293
38211979	1466	1471	Abeta	Gene	351
38211979	1532	1538	SERF1a	Gene	8293
38211979	1554	1559	Abeta	Gene	351
38211979	1587	1599	Cytotoxicity	Disease	MESH:D064420
38211979	1624	1630	SERF1a	Gene	8293
38211979	1640	1648	toxicity	Disease	MESH:D064420
38211979	1652	1657	Abeta	Gene	351
38211979	1706	1712	SERF1a	Gene	8293
38211979	1794	1800	SERF1a	Gene	8293
38211979	1811	1816	Abeta	Gene	351
38211979	1879	1881	AD	Disease	MESH:D000544
38211979	Association	MESH:D000544	8293
38211979	Association	MESH:C000718787	6622
38211979	Association	MESH:C000718787	8293
38211979	Positive_Correlation	351	8293
38211979	Positive_Correlation	MESH:C000718787	3064
38211979	Association	MESH:D000544	351
38211979	Association	MESH:C000718787	351
38211979	Positive_Correlation	MESH:D064420	8293

